Treatment guidelines identify low-density lipoprotein cholesterol (LDL-C) as the primary target of therapy with secondary targets of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apoB). Data were pooled from 27 randomised, double-blind, active or placebo-controlled trials in 21,794 adult hypercholesterolaemic patients (LDL-C 1.81-6.48 mmol/L) receiving ezetimibe/statin or statin for 4-24 weeks. Percentages of patients achieving various targets were calculated among diabetes (n = 6541) and non-diabetes (n = 15,253) subgroups. Significantly more patients with and without diabetes achieved specified levels of LDL-C (< 2.59, < 1.99, < 1.81 mmol/L), non-HDL-C (< 3.37, < 2.59 mmol/L) and apoB (< 0.9, < 0.8 g/L) with ezetimibe/statin versus statin. Patients with diabetes had larger mean per cent reductions in LDL-C and non-HDL-C than non-diabetes patients. A greater percentage of patients achieved both the LDL-C and apoB targets and all three LDL-C, apoB, and non-HDL-C targets with ezetimibe/statin versus statin in both subgroups. Patients with diabetes benefitted at least as much as, and sometimes more than, non-diabetes patients following treatment with ezetimibe/statin.
Introduction
Patients with diabetes mellitus are at increased risk for coronary heart disease (CHD)-related morbidity and mortality. The increased incidence of CHD in patients with diabetes mellitus is attributed in part to diabetic dyslipidaemia, which is characterised by low plasma levels of high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TGs), and a predominance of small, dense low-density lipoprotein cholesterol (LDL-C) particles. 1 There is extensive clinical trial evidence, primarily from studies involving statins, that lowering LDL-C levels reduces vascular events and mortality in patients with diabetes. American and European guidelines identify the primary goal of lipid-modifying therapy as LDL-C < 100 mg/dl (< 2.59 mmol/L) in patients with diabetes mellitus, with an optional level of < 70 mg/dl (< 1.81 mmol/L) in patients with diabetes mellitus at very high risk for CHD, including those with both diabetes mellitus and established CHD. [2] [3] [4] [5] Despite the proven association between elevated LDL-C levels and increased CHD risk in patients with and without diabetes mellitus, clinical results suggest that apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) levels may provide a more accurate 1 6 Merck Medical Affairs, USA assessment of future CHD risk. [6] [7] [8] [9] [10] [11] To this end, the American Diabetes Association (ADA) and American College of Cardiology Foundation (ACCF) recently released a joint consensus statement recommending non-HDL-C and apoB levels of < 130 mg/dl (< 3.37 mmol/L) and < 90 mg/dl (< 0.9 g/L), respectively, in diabetes mellitus with no other major risk factors, and non-HDL-C and apoB levels of < 100 mg/dl (< 2.59 mmol/L) and < 80 mg/dl (< 0.8 g/L), respectively, for diabetes mellitus plus one or more additional major risk factors or diabetes mellitus plus known atherosclerotic cardiovascular disease. 12 In addition to the aforementioned lipids and lipoproteins, high-sensitivity C-reactive protein (hs-CRP) is an emerging risk factor. Studies indicate that patients with the highest levels of hs-CRP have about twice the risk of cardiovascular events as those with the lowest levels. Under current AHA guidelines, an hs-CRP level < 1.0 mg/L is considered low risk, whereas 1.0 to 3.0 mg/L is average risk and ≥ 3.0 mg/L is considered high risk. 13 However, the potential value of lowering hs-CRP with pharmacologic interventions is unknown.
Statin monotherapy has been demonstrated to substantially reduce apoB-containing lipoproteins (i.e. LDL-C and non-HDL-C) and improve hs-CRP levels. Many patients fail to achieve recommended levels of LDL-C, non-HDL-C, and apoB with statins alone and therefore remain at increased risk of coronary events. [14] [15] [16] [17] Therefore, combination lipid-lowering therapies may be warranted in high-risk patients with and without diabetes mellitus to facilitate the achievement of optimal lipid and lipoprotein levels. The combination therapy regimen consisting of ezetimibe 10 mg co-administered with statin affects cholesterol metabolism through two complementary mechanisms of action: inhibition of cholesterol absorption within the intestine and inhibition of cholesterol biosynthesis in the liver.
Co-administration of ezetimibe/statin has been demonstrated to be more effective in lowering LDL-C and increasing the proportion of patients achieving treatment targets than comparable or higher doses of or more potent statin monotherapy. [18] [19] [20] [21] [22] This report describes the results of a pooled analysis of data obtained from randomised, double-blind, active-or placebo-controlled clinical studies examining the lipidaltering effects of ezetimibe/statin combination therapy, administered as either first-(i.e. in patients washed off of lipid-modifying drugs at baseline) or second-line therapy (i.e. in patients treated with statin monotherapy at baseline), in adult hypercholesterolaemic patients with and without diabetes. The purpose of this post-hoc analysis was to compare the proportions of diabetes and non-diabetes patients achieving various LDL-C (< 2.59, < 1.99, and < 1.81 mmol/L), non-HDL-C (< 3.37 and < 2.59 mmol/L) and apoB (< 0.9 and < 0.8 g/L) targets with ezetimibe/statin versus statin alone. It was of interest to determine whether diabetes patients taking ezetimibe/statin with dual mechanism of action benefitted as much as non-diabetes patients taking the same therapy.
Methods

Studies included in analysis
We have described in a paper by Leiter et al. 23 the effects of treatment on standard lipid and lipoprotein endpoints evaluated in patients with and without diabetes mellitus. This post-hoc analysis evaluated previously published, randomised, double-blind, active-or placebo-controlled clinical trials comparing the lipid-altering effects of ezetimibe/statin or statin alone that were conducted by Merck Research Laboratories at the global level to ensure full access to individual patient results. Studies were excluded from this pooled analysis if they were of crossover (n = 1) or open-label design (n = 1), were extension (n = 12) or ongoing outcome studies (n = 1), or tested ezetimibe as monotherapy (n = 10) or in combination with other lipid-lowering drugs (e.g. fenofibrate, niacin) (n = 4). Studies focusing on non-adult patients (n = 1) or patients with sitosterolaemia, homozygous familial hypercholesterolaemia, aortic stenosis, or chronic kidney disease (n = 6) also were excluded. Studies that were ongoing at the time of the analysis (n = 3), had been terminated early because of recruitment problems (n = 2), or had missing safety data (n = 1) also were excluded.
Patients and study designs
Patients were adults who were either taking no lipid medication (i.e. first-line therapy) or were receiving statin therapy (i.e. second-line therapy) at baseline prior to receiving randomised treatment assignment. The first-line therapy patients were randomised to receive double-blind ezetimibe/statin (i.e. ezetimibe/simvastatin combination tablet or ezetimibe 10 mg co-administered with simvastatin, lovastatin, pravastatin, atorvastatin) or statin alone (i.e. simvastatin, lovastatin, pravastatin, atorvastatin, or rosuvastatin) at the same dose, at double the initial dose, or after switching to a more potent statin (e.g. rosuvastatin) for up to 12 weeks.
The studies conducted in patients previously treated with statins used two general types of study design, namely an add-on therapy or switch-therapy design. In the add-on therapy studies, statin-treated patients were randomised to receive double-blind placebo or ezetimibe 10 mg administered in combination with their ongoing, previously prescribed, open-label statin (i.e. simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, or cerivastatin) for up to eight weeks. In the switch-therapy studies, statin-treated patients were switched from their ongoing, previously prescribed, open-label statin (i.e. simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, or rosuvastatin) to receive double-blind ezetimibe/statin (i.e. ezetimibe/simvastatin combination tablet) or statin alone (i.e. simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, or rosuvastatin) at the same dose, at double the initial dose, or switched to a more potent statin (e.g. rosuvastatin) for up to 24 weeks.
Patients were classified as having diabetes mellitus (predominantly type 2 with a few type 1) based on the investigator's clinical judgment, except for three studies that enrolled only patients with diabetes mellitus (i.e. only patients with diabetes mellitus based on elevated haemoglobin A1c values were eligible for inclusion in these three studies).
Statistical methods
Efficacy was assessed in a modified version of the intent-totreat population, which includes all randomised patients who have baseline values, have taken at least one dose of study medication, and have one or more post-randomization measurements. Percentage changes from baseline in lipids and other parameters at study were calculated separately for the populations of patients who did not receive lipidmodifying drugs at baseline (i.e. first-line therapy) and those who had received statin monotherapy (i.e. secondline therapy) at baseline prior to receiving randomised treatment assignment. Within these two patient populations, changes from baseline were calculated for the overall cohort (i.e. irrespective of diabetes status) and separately for those with and without diabetes. The within-and between-group changes from baseline in LDL-C, non-HDL-C, apoB, and hs-CRP were calculated.
The consistency of treatment effect between patients with and without diabetes was tested using an analysis of covariance (ANCOVA) model with terms for baseline LDL-C, age, race (White, other), body mass index, gender, baseline HDL-C, baseline TG, baseline response variable (when modelling per cent change for variables other than LDL-C, HDL-C, and TG), CHD (yes/no), statin potency (low, medium, high), first-/second-line therapy status, trial within first-/second-line therapy status, treatment (statin, ezetimibe/statin), treatment by first-/second-line therapy status interaction, diabetes versus non-diabetes classification, and treatment × diabetes/non-diabetes interaction. If the term for trial within first-/second-line therapy status and/or treatment by first-/second-line therapy status interaction was not significant, the non-significant term was dropped from the model. The least squares mean per cent change from baseline in hs-CRP was calculated as follows: [back-transformed value of the log(study end/baseline)-1] × 100% estimated from the same ANCOVA model with an additional term for first-/second-line × diabetes × treatment interaction.
The percentages of patients at various lipid, apolipoprotein, and biochemical values at study endpoint within each treatment group were assessed by a logistic regression model with terms for first-/second-line, diabetes, treatment, and baseline value(s). The same models (except diabetes term) were fitted within diabetes and non-diabetes patients. The effects of first-/second-line therapy on lipid, lipoprotein and biochemical attainment rates were determined by fitting similar models within first-line and second-line therapy studies.
Results
Patients
This post-hoc pooled analysis included data from 27 previously published, randomised, double-blind, active-or placebo-controlled clinical trials conducted in 21,794 adult patients (age range 18-81 years) with elevated LDL-C (range > 1.81-6.48 mmol/L [70-250 mg/dL]) receiving ezetimibe/statin or statin alone for 4-24 weeks. Within each patient subgroup (i.e. first-and second-line therapy and the absence/presence of diabetes at randomization), baseline demographic and lipid/lipoprotein characteristics were generally well balanced across the ezetimibe/statin and statin groups ( Table 1) . Patients in the first-line therapy subgroup were generally younger than patients in the second-line therapy subgroup and fewer of them had a prior history of CHD ( Table 1) . Irrespective of first-or second-line therapy classification, patients with diabetes had a higher mean body mass index and higher mean HbA 1c values at baseline compared with mean values for patients without diabetes. Patients with diabetes also demonstrated lipid/lipoprotein abnormalities typical of patients with diabetes mellitus, including high TG and low HDL-C levels at baseline. Patients with diabetes also had lower baseline LDL-C and TC levels compared with patients without diabetes ( Table 2) .
Effects on lipids and lipoproteins
Irrespective of first-/second-line therapy and diabetes/nondiabetes classification, treatment with ezetimibe/statin compared with statin alone led to significantly greater reductions from baseline in LDL-C (p < 0.0001), non-HDL-C (p < 0.0001), and apoB (p < 0.0001) at study endpoint ( Table 2 ). Significant treatment × first-/second-line therapy interaction terms were observed for these efficacy parameters evaluated (p < 0.0001), indicating that patients who received statin monotherapy at baseline achieved significantly larger between-treatment group differences in LDL-C, non-HDL-C, and apoB compared with patients who did not receive lipid-modifying drugs at baseline (Table 3 ). Significant treatment × diabetes/non-diabetes interaction terms were observed for LDL-C (p < 0.0001) and non-HDL-C (p < 0.0001), indicating that patients with diabetes achieved significantly larger between-treatment group improvements in these lipid parameters compared with patients without diabetes ( Table 2 ). The lack of significant treatment × diabetes interaction terms for apoB (p = 0.0782) indicated that the magnitude of the betweentreatment group differences in these parameters were consistent across the patient subgroups ( Table 2) .
Effects on hs-CRP
Irrespective of first-/second-line therapy and diabetes/ non-diabetes classification, treatment with ezetimibe/statin compared with statin alone led to significantly greater reductions from baseline in hs-CRP (p < 0.005) at study endpoint ( Table 2 ). Significant treatment × first-/second-line therapy interaction terms were not observed for hs-CRP ( Table 3 ). The lack of a significant treatment × first-/ second-line therapy interaction term for hs-CRP indicated that first-and second-line therapy patients achieved similar magnitude between-treatment reductions in hs-CRP at study endpoint.
The lack of significant treatment × diabetes interaction terms for hs-CRP (p = 0.4993) indicated that the magnitude of the between-treatment group differences in these parameters were consistent across the patient subgroups ( Table 2 ).
Proportion of patients achieving various potential lipid and lipoprotein levels at study endpoint
Treatment with ezetimibe/statin compared with statin alone resulted in significantly higher proportions of patients with specified single (Table 3 ; Figure 1, A, B and C) and multiple (i.e. double and triple) ( Table 4 ; Figure 2, A and B ) LDL-C, non-HDL-C, and apoB levels irrespective of first-/ second-line therapy and diabetes/non-diabetes classification (i.e. the 95% confidence intervals [CIs] for betweentreatment comparisons [ezetimibe/statin vs. statin alone] of odds ratios excluded 1.00 for the overall population and within the diabetes/non-diabetes groups). The observed proportions of patients achieving specified single (Table 3 ; Figure 1, A, B and C) and multiple (Table 4 ; Figure 2 , A and B) LDL-C, non-HDL-C, and apoB levels with ezetimibe/ statin and statin alone were numerically higher for first-line therapy patients than for second-line therapy patients both in the overall population and broken down by diabetes status. First-line therapy patients were approximately 2.0 to 2.7 times more likely to achieve specified single and multiple LDL-C, non-HDL-C, and apoB levels with ezetimibe/ statin versus statin alone at study endpoint (Tables 3 and 4 ). Second-line therapy patients were approximately 2.4 to 3.9 times more likely to achieve specified single and multiple LDL-C, non-HDL-C, and apoB levels with ezetimibe/statin versus statin alone at study endpoint (Tables 3 and 4 ).
Patients with diabetes were more likely than those without diabetes to attain single and multiple LDL-C, non-HDL-C, and apoB targets following treatment with ezetimibe/ statin and statin alone (Figures 1 and 2) . However, this appeared to result from patient selection, since patients with diabetes had baseline LDL-C and non-HDL-C levels 0.4 to 0.7 mmol/L lower than non-diabetes patients as well as slightly lower baseline apoB levels.
Proportion of patients achieving various hs-CRP levels at study endpoint
Treatment with ezetimibe/statin compared with statin alone generally resulted in significantly higher proportions of patients with single hs-CRP values of < 2 mg/L and < 1 mg/L at study endpoint irrespective of first-/second-line therapy and diabetes/non-diabetes classification ( Table 3 and Figure 1D ). Among first-line therapy patients, the only exception was the finding of non-significant betweengroup differences in the proportions of diabetes patients with specified hs-CRP values < 2 mg/L and < 1 mg/L Figure 1 . Percentage of patients by diabetes status and first-or second-line therapy who achieved specified levels of LDL-C (A), non-HDL-C (B), apoB (C), and hs-CRP (D) at study endpoint. Asterisks over columns refer to point estimate of odds ratio attaining recommended level taking ezetimibe/statin versus statin is greater than 1; both limits of the 95% CI on odds ratio exceed 1.
( Figure 1D ). Among second-line therapy patients, the only exception was the finding of a non-significant betweengroup difference in the proportion of non-diabetes patients with specified hs-CRP values < 2 mg/L ( Figure 1D ). The proportions of patients with specified hs-CRP values of < 2 mg/L and < 1 mg/L at study endpoint were similar across the first-and second-line therapy groups both when examined in the overall population and when broken down by diabetes status (Table 3 ; Figure 1D ).
Discussion
Cholesterol treatment guidelines emphasise LDL-C lowering as the primary target of lipid-lowering therapy in hypercholesterolaemic patients with and without a history of diabetes. Non-HDL-C, apoB, and hs-CRP are identified as secondary targets or emerging risk factors that may warrant intervention in certain patient populations. Many statintreated patients have high circulating levels of other atherogenic particles (i.e. non-HDL-C and apoB) and thus remain at increased risk for future coronary events even when LDL-C goals are met. This is especially true for insulin resistant patients who typically present with a form of dyslipidaemia characterised by normal to slightly elevated LDL-C levels, mild hypertriglyceridaemia, low HDL-C levels, elevated levels of cholesterol-rich remnant particles, and a preponderance of small, dense LDL-C particles. In addition, an inflammatory process is believed to play a role in the formation and progression of atherosclerotic plzcxues. 24, 25 The inflammatory marker hs-CRP has been shown to predict CHD-related morbidity and mortality independent of traditional lipid/lipoprotein risk factors. [24] [25] [26] [27] Previous studies demonstrated that statins reduce hs-CRP levels and ezetimibe 10 mg administered in combination with statins produces further incremental reductions in hs-CRP beyond that achieved with statins alone. 28 Thus, the use of combination lipid-lowering therapies with two different and complementary modes of action may be warranted in high-risk patients with and without diabetes to improve the overall risk profile.
The present pooled analysis of data from 21,794 patients compared the proportions of hypercholesterolaemic patients with and without diabetes achieving various lipoprotein and hs-CRP levels following treatment with ezetimibe/statin therapy (pooled across statin dose/type) versus statin monotherapy (pooled across statin dose/type) administered as either first-line (i.e. patients were washed off of all lipid-lowering therapies prior to study drug) or second-line therapy (i.e. in statin-treated patients). Significantly greater between-treatment group improvements from baseline in LDL-C, non-HDL-C, apoB, and hs-CRP were seen following treatment with ezetimibe/statin combination therapy versus statin monotherapy irrespective of diabetes/non-diabetes classification or whether the study medication was administered as first-or second-line therapy. The observed between-treatment group (i.e. ezetimibe/statin vs. statin alone) reductions from baseline in LDL-C and non-HDL-C were larger in patients with diabetes than in those without diabetes, whereas patients with and without diabetes demonstrated similar magnitude reductions from baseline in apoB and hs-CRP. The enhanced lipid-and apoB-lowering efficacy of ezetimibe/statin co-administration resulted in significantly more patients achieving specified single, dual, and triple LDL-C, non-HDL-C, and apoB levels at study endpoint (after adjusting for baseline differences) irrespective of first-/second-line therapy and diabetes/non-diabetes classification. Patients with diabetes showed the same advantages for ezetimibe/statin in attainment of targets as non-diabetes patients. Numerically higher goal attainment rates for patients with diabetes compared with non-diabetes patients in this pooled analysis were likely related to lower baseline levels of LDL-C, non-HDL-C, and apoB among patients with diabetes.
Several previous studies have demonstrated greater LDL-C-and non-HDL-C-lowering effects of ezetimibe 10 mg used either alone or in combination with statins in patients with diabetes versus those without diabetes. 29 Mechanistic evidence supporting the enhanced efficacy of ezetimibe 10 mg in diabetic patients versus non-diabetic patients include observed differences in cholesterol metabolism between these two patient groups. Studies have previously demonstrated that cholesterol synthesis is enhanced and cholesterol absorption is reduced in patients with diabetes. 12 In addition, mRNA expression of Neimann Pick C1-like 1 protein (NPC1L1), the specific target of ezetimibe, is increased both in animal models of diabetes as well as in patients with diabetes mellitus. 13, 20 Furthermore, the mRNA expression of the ATP binding cassette proteins (ABC) G5 and G8 have been shown to be decreased in patients with diabetes mellitus thereby increasing the delivery of cholesterol for absorption. 13, 20 Taken together, these findings suggest that differences in cholesterol metabolism may be responsible for the enhanced LDL-C-and non-HDL-C-lowering efficacy of ezetimibe/statin seen in this pooled analysis of patients with diabetes versus those without diabetes.
The enhanced hs-CRP-lowering efficacy of the ezetimibe/ statin co-administration regimen seen in the current pooled analysis also resulted in significantly more patients with hs-CRP values < 2 mg/L and < 1 mg/L at study endpoint (after adjusting for baseline differences) in the overall population. However, improvements in the proportion of patients with specified hs-CRP levels following treatment with ezetimibe-statin versus statin alone were numerically smaller than those seen for lipid/lipoprotein targets. In some subgroups (e.g. first-line treatment among patients with diabetes), no improvement was observed. Patients with diabetes versus those without diabetes reached specified hs-CRP values at study endpoint with similar frequencies, irrespective of whether the treatments were administered as first-or second-line therapy.
Overall, the results of the present pooled analysis are consistent with previous studies showing the greater lipid/ lipoprotein/hs-CRP-lowering effects of ezetimibe/statin combination therapy versus statin alone across both patient subgroups with and without diabetes. [30] [31] [32] [33] [34] [35] In addition, several studies have previously demonstrated an enhanced ability of ezetimibe/statin therapy to facilitate the attainment of LDL-C goals relative to that seen with statin monotherapy. 34, 36, 37 The current analysis confirms these previous findings and extends them to include the enhanced ability of ezetimibe/statin versus statin monotherapy to facilitate optimal apoB and non-HDL-C levels in patients with and without diabetes. Percentage of patients by diabetes status and first-or second-line therapy who achieved dual (A) and triple (B) LDL-C, non-HDL-C, and apoB targets at study endpoint. Asterisks over columns refer to point estimate of odds ratio attaining recommended levels taking ezetimibe/statin versus statin is greater than 1; both limits of the 95% CI on odds ratio exceed 1.
The present analysis has several limitations that should be considered when evaluating these results. First, this was an exploratory post hoc analysis; thus, the results should be interpreted with caution. However, our findings are consistent with several prior studies showing the superior lipidlowering efficacy of ezetimibe/statin combination therapy versus statin alone in patients with diabetes. In addition, the ezetimibe/statin and statin alone groups consist of a collection of results pooled across all statin doses and types used in the respective studies. As such, we are not able to compare treatment effects of ezetimibe/statin and statin alone at comparable or equipotent dosages. The recent placebocontrolled Study of Heart and Renal Protection (SHARP) demonstrated that ezetimibe + simvastatin (10/20 mg) safely reduced cardiovascular events in patients with advanced chronic kidney disease. 38 The incremental effect of ezetimibe on cardiovascular outcomes beyond a statin thereby is the specific focus of the ongoing Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). 39, 40 In summary, this pooled analysis confirms the superior lipid/lipoprotein-lowering efficacy of ezetimibe/statin therapy relative to statin alone in hypercholesterolaemic patients with and without diabetes, and demonstrates that the combination regimen facilitates the achievement of specified LDL-C, non-HDL-C, and apoB levels. Thus, through dual inhibition of cholesterol absorption and synthesis, ezetimibe/statin confers patients with as well as those without diabetes with an enhanced ability to achieve optimal lipid/lipoprotein levels.
